Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference Read more about Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference
Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call Read more about Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease Read more about Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel Read more about Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
Xencor Initiates Phase 1b/2a Trial of XmAb®5871 for Autoimmune Disease Read more about Xencor Initiates Phase 1b/2a Trial of XmAb®5871 for Autoimmune Disease
Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference Read more about Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference
Xencor Reports Second Quarter 2014 Financial Results Read more about Xencor Reports Second Quarter 2014 Financial Results
Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call Read more about Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer Read more about Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
Xencor Initiates Phase 1 Study of XmAb7195 for Asthma Read more about Xencor Initiates Phase 1 Study of XmAb7195 for Asthma
